You are viewing a single comment's thread from:
RE: Molecules to Mental States: MDMA
MDMA overview here is very descriptive, but I think it is too much for the general public. Otherwise, I enjoyed the post and look forward to seeing the results of some of the ongoing clinical trials being conducted in Europe. Too bad the US has this drug classified as schedule 2. Very tough to study in patients.
It's schedule 1 here in the US, which makes it ridiculously difficult to get/test/research to prove whether or not it truly belongs in that category. The research is promising but as others have stated the risk/benefit ratio MAY not bear fruit. We have a difficult enough time getting our regulators to take cannabis off the schedule 1 list despite billions of doses being used. Tough times for a potentially useful compound ripe for investogation.
Thanks!!! Very tough indeed. The Rick Doblin (MAPS) interview does a great job of covering some of these difficulties. It is quite ridiculous what they make researchers go through (and pay)